Barberry Powder for Blood Pressure: What One RCT Found

Barberry powder lowered systolic blood pressure in a randomized trial, but it was tested only as an add-on to standard antihypertensive drugs. That is the useful result—and the limit of the result. It offers an early signal for medicated people with hypertension, not evidence that barberry can replace an ACE inhibitor, ARB, calcium-channel blocker, or diuretic.

The trial used 10 g per day of dried purple-black barberry (Berberis integerrima) for eight weeks. Participants taking barberry had statistically significant reductions in systolic blood pressure and mean arterial pressure compared with placebo. The publication's abstract reports p-values, not the actual millimeters-of-mercury changes. Without those numbers, nobody can tell whether the average benefit was clinically modest or large.

What the barberry trial actually tested

In the 2022 randomized, double-blind, placebo-controlled trial by Emamat et al., 84 adults with cardiovascular risk factors enrolled and 78 completed the study. Their mean age was 54.12 years, and all were already taking antihypertensive medication. Researchers assigned participants to 10 g daily of dried B. integerrima powder or placebo for two months.

After adjustment for baseline values and changes in 24-hour urinary sodium, the barberry group had lower systolic blood pressure than the placebo group (p=0.015) and lower mean arterial pressure (p=0.008). The available abstract does not report a statistically significant diastolic-pressure result, nor does it provide the mean blood-pressure changes or confidence intervals.

Those omissions matter. A p-value tells us how compatible the observed difference is with a no-effect result under the study's statistical model. It does not tell a clinician whether the difference was 2 mmHg, 12 mmHg, durable, or large enough to change treatment decisions. The trial also cannot separate a direct effect of barberry from an additive effect or interaction with the participants' background medications. For the people actually studied, however, an additive effect is the relevant clinical question.

Barberry has one small human trial as an adjunct to blood-pressure medication. It has no human trial evidence as a replacement for medication or as a treatment for people with normal blood pressure.

A nitric-oxide clue, not a proven mechanism

The trial measured markers related to nitric oxide, a signaling molecule involved in blood-vessel function. Urinary nitrate plus nitrite (NOx) rose significantly in the barberry group (p=0.008). Plasma NOx and angiotensin-converting enzyme activity did not differ significantly between groups.

That split result makes for an interesting lead, not a solved pathway. Systemic endothelial nitric-oxide activity could contribute to lower pressure, but urinary NOx alone cannot establish it. Renal handling, diet, and gut microbial metabolism can also affect urinary NOx. A systematic review and meta-analysis of inorganic nitrate supplementation in older adults provides useful context: nitrate-pathway interventions can change NO-related measures without producing a simple, consistent blood-pressure story in every setting.

Barberry's result therefore does not prove that it lowered pressure by increasing endothelial nitric oxide. The unchanged plasma NOx and ACE activity leave several possibilities open, including a renal or gut-compartment effect. Biomarkers can help generate hypotheses; they do not get to declare themselves the culprit.

Where berberine fits—and where it does not

Barberry species contain isoquinoline alkaloids, including berberine, and that chemistry gives the finding some biological plausibility. A 2022 review of vascular-protective phytocompounds describes endothelial and antioxidant actions proposed for berberine. A 2025 review of natural products in cardiovascular disease likewise discusses berberine's anti-inflammatory and antioxidant properties.

These reviews support a reasonable hypothesis that berberine-class compounds could affect vascular biology. They do not establish that berberine caused the blood-pressure change in the barberry trial. The intervention was whole B. integerrima fruit powder, and the study did not characterize its berberine or other alkaloid content. A 10 g serving of one batch therefore cannot be translated into a purified-berberine dose, or assumed equivalent to a product sold under the same common name.

A 2025 Bayesian network meta-analysis by Miao et al. found favorable composite cardiometabolic effects for berberine among people with type 2 diabetes. That is supportive background evidence, but it cannot quantify barberry powder's blood-pressure effect. The population differed, the analysis included other phytocompounds, and the available findings do not isolate a berberine-specific blood-pressure estimate.

How this compares with better-developed blood-pressure adjuncts

Food-derived and behavioral add-ons can lower blood pressure; barberry is not entering an empty field. The difference is evidentiary maturity. A 2024 systematic review and meta-analysis of beetroot juice evaluated randomized trials in adults with hypertension under European Society of Hypertension criteria. A meta-analysis of high-intensity interval training included nine randomized trials and 569 patients with hypertension. A 2025 review of edible algae trials also assessed blood-pressure outcomes in adults after interventions lasting at least four weeks.

Those interventions vary in practicality, mechanism, dose, and patient population. They should not be treated as head-to-head competitors with barberry. Still, they show why replication and transparent effect estimates matter: blood-pressure research is full of plausible interventions, and the ones that become useful usually have more than a single small study behind them.

Even periodontal treatment illustrates the need to read estimates rather than headlines. A 2022 meta-analysis of eight randomized trials reported weighted mean differences of −4.3 mmHg for systolic pressure and −3.16 mmHg for diastolic pressure for intensive versus conventional periodontal therapy, but both 95% confidence intervals included zero and the reported p-values were 0.08 and 0.06. The estimates may be clinically interesting, but that analysis did not meet conventional statistical-significance thresholds. Barberry has the opposite interpretive problem: its reported p-values crossed those thresholds, but the absolute effect sizes are unavailable in the abstract.

The safety problem is bigger than the efficacy question

Every participant in the barberry trial used antihypertensive medication, yet the available study does not provide pharmacokinetic or pharmacodynamic interaction data with common blood-pressure drugs. That gap matters before anyone tries to self-experiment. An add-on that lowers pressure could be useful; an add-on that pushes pressure too low, changes drug exposure, or complicates a stable regimen needs supervision.

Berberine has been reported to inhibit CYP3A4 and CYP2D6 in preclinical and limited clinical research, although those interaction findings do not establish the effect of this particular whole-fruit powder. The practical conclusion remains cautious: people taking antihypertensives should discuss barberry or berberine products with the clinician or pharmacist who manages their medications. Home blood-pressure readings are useful data, but they are not a substitute for an interaction assessment.

What would make the evidence persuasive?

A stronger trial would enroll at least 200 participants, report the absolute systolic and diastolic changes in mmHg with confidence intervals, and replicate the finding outside one site and population. It would include carefully characterized barberry powder, test more than one dose, track adverse events and drug interactions, and ideally compare a whole-barberry preparation with purified berberine. A drug-naive arm would answer a different but important question: whether barberry has measurable effects without background antihypertensive therapy.

For now, the evidence supports a narrow conclusion. In one eight-week, placebo-controlled trial among medicated adults with cardiovascular risk factors, 10 g daily of dried purple-black barberry powder was associated with statistically significant reductions in systolic blood pressure and mean arterial pressure. The clinical size of that benefit, the mechanism, reproducibility, product standardization, and medication safety remain unresolved. That is enough to justify more research, not enough to justify casual substitution or unsupervised stacking.